PCV46 - Treatment Patterns And Drug Adherence In Patients With Hypertension And Dyslipidemia: Korean HTN/DYS Outcomes Research Group

Abstract

This study aimed to examine treatment patterns and drug adherence of hypertensive patients accompanying with dyslipidemia in Korea. A prospective, observational study was conducted at 18-tertiary-hospital from May, 2013 to July, 2015. Hypertensive patients accompanying with dyslipidemia receiving both hypertension and dyslipidemia drugs were enrolled for 6months and followed for consecutive 6months. Patients with renal or liver disorders were excluded, which defined as followings;1)Creatinine clearance(CrCL)<30 mL/min, 2)serum creatinine(SCR)≥2mg/dL, 3)1.5times greater than upper limits of normal SCR or 4)2times greater than upper limit of normal AST/AST. Data collection was performed through medical record review and patient survey. Data on demography and clinical characteristics was collected at baseline, and treatment patterns and drug adherence were investigated at 2, 4 and 6months. Drug adherence was estimated with pill-count and patients were determined as adherent if they administered ≥80% of prescribed pills. A total of 1,051 patients(age:62.5±9.6,female:52.0%) included. At baseline, blood pressure and total cholesterol were 129.2/77.6mmHg and 177.4mg/dL on average. Duration of hypertension and dyslipidemia was 8.6 and 4.6years. 64.8% of total patients had underlying diseases including mostly cardiac diseases(52.0%) and diabetes(25.3%). For hypertensive drugs, β-blocker(34.8%) was the most commonly prescribed drug class and followed by ARB(27.7%) and CCB(22.3%). Statin(91.7%) was the dominant class of drugs and Fibrates(3.3%) and Ezetimible(2.2%) were also included for dyslipidemia treatment. To treat both hypertension and dyslipidemia, single pill of CCB combined with ARB was the most frequently prescribed drug class and CCB combined with statin was second leading drug class. Drug adherence rate was 90.6% on average, and 86.3% of total study population was adherent to their drugs for study period. Drug adherence rate was significantly decreased during follow-up over the study(β=-2.3, p<.0001). These study results indicated that drug adherence should be considered while setting the management strategies for hypertension and dyslipidemia, which requires a life-long treatment.